ReviewTranslational cancer research2024
Winning hearts & minds: prostate cancer outreach and clinical trial enrollment in minority men.
Review in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors associated with clinical research participation among Medicare beneficiaries with prostate cancer in the United States.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minorities participate less than White people in a variety of research settings limiting the generalizability of the research results. The driving forces behind the lower participation rates are multifactorial and vary by race. Further compounding these driving forces are past inequities and violations of trust by the healthcare system. Addressing these issues is crucial to equitably accruing within clinical trials and subsequently addressing the lack of generalizable results being produced. Despite legislation being enacted to increase the enrollment of minorities in clinical trials, the participation rates remain low with cancer clinical trials being particularly disparate in terms of equitable representation. As prostate cancer disproportionately affects Black men, it is imperative that prostate cancer clinical trials enroll an equitable number of Black men. Previous trials including the Prostate, Lung, Colorectal, and Ovarian multicenter randomized trial and the Prostate Cancer Prevention Trial both involved concerted efforts to address the relatively low participation rate of minority men, but both were not successful in that regard. To facilitate equal access and ensure the appropriate participation of minorities in prostate cancer clinical trials, various interventions from additional safety assurances to consenting patients as a family unit have been employed, depending on the community. Overall, progress is being made in equitably accruing clinical trials, but there remains more work to be done.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.